1. Home
  2. LMAT vs MESO Comparison

LMAT vs MESO Comparison

Compare LMAT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeMaitre Vascular Inc.

LMAT

LeMaitre Vascular Inc.

HOLD

Current Price

$103.56

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.50

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMAT
MESO
Founded
1983
2004
Country
United States
Australia
Employees
N/A
81
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
LMAT
MESO
Price
$103.56
$14.50
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$105.80
N/A
AVG Volume (30 Days)
250.9K
272.5K
Earning Date
05-05-2026
02-26-2026
Dividend Yield
0.93%
N/A
EPS Growth
30.57
N/A
EPS
0.68
N/A
Revenue
$249,602,000.00
N/A
Revenue This Year
$14.21
$629.74
Revenue Next Year
$8.88
$30.65
P/E Ratio
$152.37
N/A
Revenue Growth
13.53
N/A
52 Week Low
$79.40
$12.66
52 Week High
$118.01
$21.50

Technical Indicators

Market Signals
Indicator
LMAT
MESO
Relative Strength Index (RSI) 57.85 42.56
Support Level $95.41 $13.82
Resistance Level $105.17 $16.06
Average True Range (ATR) 3.58 0.61
MACD 0.21 -0.29
Stochastic Oscillator 77.18 6.54

Price Performance

Historical Comparison
LMAT
MESO

About LMAT LeMaitre Vascular Inc.

LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: